Cargando…

The new Veterinary Medicines Regulation: rising to the challenge

This article focuses on the new Veterinary Medicines Regulation, which is applicable across all Member States of the European Union, including Ireland, from 28 January 2022. From this date, prophylactic use of antimicrobials (AMs) in groups of animals is banned, metaphylactic use in groups of animal...

Descripción completa

Detalles Bibliográficos
Autores principales: More, Simon J., McCoy, Finola, McAloon, Catherine I.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8812186/
https://www.ncbi.nlm.nih.gov/pubmed/35115047
http://dx.doi.org/10.1186/s13620-022-00209-6
_version_ 1784644596208238592
author More, Simon J.
McCoy, Finola
McAloon, Catherine I.
author_facet More, Simon J.
McCoy, Finola
McAloon, Catherine I.
author_sort More, Simon J.
collection PubMed
description This article focuses on the new Veterinary Medicines Regulation, which is applicable across all Member States of the European Union, including Ireland, from 28 January 2022. From this date, prophylactic use of antimicrobials (AMs) in groups of animals is banned, metaphylactic use in groups of animals is restricted, and certain AMs are reserved for humans only. In the Irish dairy industry, as elsewhere, successful implementation of the Regulation will require a high level of mastitis control across all herds, and measures to support high standards in antibiotic stewardship. National actions will be critical, to support optimal mastitis control throughout the national herd. For private veterinary practitioners (PVPs), the Regulation will lead to specific prescribing changes, including the requirement to shift from blanket to selective dry cow therapy. Further, prescribing choices will need to be guided by the categorisation for AMs developed by the European Medicines Agency (EMA). More broadly, the Regulation requires a fundamental shift in thinking both in terms of AM usage and of the role of the PVP. Given the close association between mastitis control and intramammary AM stewardship, it is imperative that prescribing and mastitis control decisions are made concurrently. A herd health approach will be critical, within a Client-Patient-Practice Relationship as outlined by the Veterinary Council of Ireland. On those farms with sub-optimal mastitis control, mastitis issues need to be sustainably resolved. A detailed farm investigation by the PVP, in partnership with the farmer and other milk quality professionals, is essential, to understand the epidemiology and on-farm drivers of mastitis, to develop farm-specific action plans, and to facilitate ongoing monitoring of progress. It is vital that PVPs provide leadership, with the provision of a holistic, herd health approach to inform both prescribing and mastitis control decisions in herds under their care.
format Online
Article
Text
id pubmed-8812186
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-88121862022-02-03 The new Veterinary Medicines Regulation: rising to the challenge More, Simon J. McCoy, Finola McAloon, Catherine I. Ir Vet J Commentary This article focuses on the new Veterinary Medicines Regulation, which is applicable across all Member States of the European Union, including Ireland, from 28 January 2022. From this date, prophylactic use of antimicrobials (AMs) in groups of animals is banned, metaphylactic use in groups of animals is restricted, and certain AMs are reserved for humans only. In the Irish dairy industry, as elsewhere, successful implementation of the Regulation will require a high level of mastitis control across all herds, and measures to support high standards in antibiotic stewardship. National actions will be critical, to support optimal mastitis control throughout the national herd. For private veterinary practitioners (PVPs), the Regulation will lead to specific prescribing changes, including the requirement to shift from blanket to selective dry cow therapy. Further, prescribing choices will need to be guided by the categorisation for AMs developed by the European Medicines Agency (EMA). More broadly, the Regulation requires a fundamental shift in thinking both in terms of AM usage and of the role of the PVP. Given the close association between mastitis control and intramammary AM stewardship, it is imperative that prescribing and mastitis control decisions are made concurrently. A herd health approach will be critical, within a Client-Patient-Practice Relationship as outlined by the Veterinary Council of Ireland. On those farms with sub-optimal mastitis control, mastitis issues need to be sustainably resolved. A detailed farm investigation by the PVP, in partnership with the farmer and other milk quality professionals, is essential, to understand the epidemiology and on-farm drivers of mastitis, to develop farm-specific action plans, and to facilitate ongoing monitoring of progress. It is vital that PVPs provide leadership, with the provision of a holistic, herd health approach to inform both prescribing and mastitis control decisions in herds under their care. BioMed Central 2022-02-03 /pmc/articles/PMC8812186/ /pubmed/35115047 http://dx.doi.org/10.1186/s13620-022-00209-6 Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Commentary
More, Simon J.
McCoy, Finola
McAloon, Catherine I.
The new Veterinary Medicines Regulation: rising to the challenge
title The new Veterinary Medicines Regulation: rising to the challenge
title_full The new Veterinary Medicines Regulation: rising to the challenge
title_fullStr The new Veterinary Medicines Regulation: rising to the challenge
title_full_unstemmed The new Veterinary Medicines Regulation: rising to the challenge
title_short The new Veterinary Medicines Regulation: rising to the challenge
title_sort new veterinary medicines regulation: rising to the challenge
topic Commentary
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8812186/
https://www.ncbi.nlm.nih.gov/pubmed/35115047
http://dx.doi.org/10.1186/s13620-022-00209-6
work_keys_str_mv AT moresimonj thenewveterinarymedicinesregulationrisingtothechallenge
AT mccoyfinola thenewveterinarymedicinesregulationrisingtothechallenge
AT mcalooncatherinei thenewveterinarymedicinesregulationrisingtothechallenge
AT moresimonj newveterinarymedicinesregulationrisingtothechallenge
AT mccoyfinola newveterinarymedicinesregulationrisingtothechallenge
AT mcalooncatherinei newveterinarymedicinesregulationrisingtothechallenge